Orphix is a pharmaceutical regulatory consulting group which has been supporting clients with the development of orphan drugs in Europe and the United States since 2002.
Our mission is to provide a high quality, bespoke and flexible service to clients enabling them to advance the development of innovative medicines for the maximum benefit of patients.
Orphix provides a tailored consulting service offering high level scientific and regulatory expertise, mainly to small and medium sized (SME) biotech companies, assisting with the development of highly-innovative products for the prevention or treatment of rare diseases.
We have a dedicated, experienced and multilingual team of regulatory consultants, who work closely with several regulatory agencies.
Orphix offers core expertise in orphan drugs, paediatric investigational plans, scientific advice meetings and electronic submissions.
Our team brings passion, expertise and unfaltering dedication. We deliver service excellence to maximise successful outcomes for our clients.